top of page

NEWS

BioStar Capital Elements Image

Our venture capital funds focus on promising technologies that have made positive impacts across the globe.

June 6, 2024

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

Read More

April 11, 2024

Nectero Medical Announces Completion of $96M Series D Financing

Read More

April 8, 2024

MMI Receives FDA Authorization to Commercialize Symani Surgical System in the U.S.

Read More

March 6, 2024

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Read More

February 29, 2024

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Read More

February 27, 2024

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

Read More

February 27, 2024

Foldax, Inc. Signs Manufacturing Agreement with Dolphin Life Science India LLP to Expedite Upcoming Commercial Availability

Read More

February 21, 2024

MMI Raises $110 Million in Series C Financing

Read More

January 12, 2024

Mark Toland, BioStar Managing Director: Medical Innovation Must Shift Focus From Common Problems to Unsolvable Ones

Read More

December 6, 2023

BioStar Capital Closes Fund V at $130.3 Million, Surpassing Previous Funds

Read More

April 18, 2023

2023 Midwest Growth Capital Symposium to Feature Louis Cannon and Dug Song as Keynotes   

Read More

April 11, 2023

AVS Appoints Sean Gilligan as Chief Operating Officer

Read More

April 4, 2023

AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round

Read More

March 16, 2023

BioStar Capital, Top 20 Venture Capital Firm 2023: Fueling Medtech Innovations with Uncompromised Fund Performance (Financial Services Review)

Read More

March 2, 2023

MMI Named One of Fast Company’s 2023 “World’s Most Innovative Companies”

Read More

January 17, 2023

BioStar Capital in The Wall Street Journal: Venture Interest in Medical Devices Holds Up, but Investors Are Choosy   

Read More

January 5, 2023

AVS Raises $20 Million in Series B Round to Advance Pulsatile Intravascular Lithotripsy (PIVL) Solutions

Read More

January 4, 2023

MMI to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More

September 15, 2022

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Read More

September 13, 2022

MedTech Strategist Article: Foldax advances the Next Big Thing in Heart Valves: Robotic Manufacturing

Read More

August 9, 2022

REVA Medical Announces Closing of Strategic Financing

Read More

July 27, 2022

Medtech Money Podcast, Episode 85: Louis Cannon, Founder & Senior Managing Director at BioStar Capital   

Read More

July 20, 2022

Medical Microinstruments Secures $75M to Advance Robotic Microsurgery

Read More

July 12, 2022

Medtronic signs $585m option to buy Israeli medtech firm CathWorks

Read More

June 17, 2022

Senseonics lands CE mark for 6-month CGM implant, teeing up Q3 launch in Europe

Read More

June 13, 2022

Ablative Solutions, Inc. Announces Completion of the Fourth Tranche of its Series D Preferred Financing Round for Unique Therapeutic Approach to Treating Uncontrolled Hypertension

Read More

June 10, 2022

REVA Medical presents 6-month results from MOTIV BTK pilot study

Read More

May 24, 2022

REVA Medical announces final 5 year results for its FANTOM II coronary scaffold study

Read More

May 11, 2022

This Company Is Reinventing the Heart Valve

Read More

May 3, 2022

First Patients Outside of U.S. Treated with TRIA Biopolymer Surgical Aortic Heart Valve in India Clinical Trial

Read More

March 30, 2022

Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies

Read More

January 18, 2022

Foldax Appoints Scott Huennekens to Board of Directors

Read More

January 5, 2022

Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’

Read More

bottom of page